Compare PLX & CNTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLX | CNTN |
|---|---|---|
| Founded | 1993 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 182.9M | 178.5M |
| IPO Year | 1996 | 2021 |
| Metric | PLX | CNTN |
|---|---|---|
| Price | $2.72 | $2.25 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 709.3K | 679.5K |
| Earning Date | 08-12-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 88.10 |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $52,744,000.00 | N/A |
| Revenue This Year | $55.77 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.07 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.60 | $1.75 |
| 52 Week High | $3.19 | $5.27 |
| Indicator | PLX | CNTN |
|---|---|---|
| Relative Strength Index (RSI) | 54.49 | 48.80 |
| Support Level | $2.59 | $1.91 |
| Resistance Level | $2.75 | $2.40 |
| Average True Range (ATR) | 0.09 | 0.19 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 46.09 | 23.74 |
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.
Canton Strategic Holdings Inc is engaged in activities related to Canton Network, including the use of Canton Coin, to support blockchain-based infrastructure and the digitization of financial market processes. The company operates in two reportable segments: digital asset treasury and clinical stage bio-technology. Its flagship clinical asset, GV104, is being developed for a specific indication for respiratory and/or nervous system depression in military personnel and chemical incident responders. The expanded pipeline includes other indications for GV104 and GV023, an approach to autoimmune diseases as well as an early-stage multispecific biologic platform.